DICE Therapeutics Inc. (DICE)

Name: DICE Therapeutics Inc. (DICE) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: DICE Therapeutics Inc. (DICE)

Stock Card

$47.55

$0.00 (0.00%)

As on 18-Aug-2023 09:30EDT

Market cap

$2,271 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

5.9

Div. Yield

0 %

DICE Therapeutics (DICE) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 47.55 High: 47.55

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-104 Mln
ROE

-0.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-17.3
Debt to Equity

0
Book Value

$--
EPS

$-2.2
Face value

--
Shares outstanding

47,755,900

Years Aggregate

CFO

$--

EBITDA

$--

Net Profit

$--

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
DICE Therapeutics (DICE)	52.4	1.8	42.7	143.0	--	--	--
BSE Sensex^*	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 18-Aug-2023 | *As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2022
DICE Therapeutics (DICE)	23.3
S&P Small-Cap 600	-17.4
BSE Sensex	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About DICE Therapeutics (DICE)

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to... modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California. Read more

Founder, CEO & Director

Dr. J. Kevin Judice Ph.D.
Founder, CEO & Director

Dr. J. Kevin Judice Ph.D.
Headquarters

South San Francisco, CA
Website

https://www.dicemolecules.com

FAQs for DICE Therapeutics (DICE)

What is the current share price of DICE Therapeutics Inc (DICE) Today?

The share price of DICE Therapeutics Inc (DICE) is $47.55 (NASDAQ) as of 18-Aug-2023 09:30 EDT. DICE Therapeutics Inc (DICE) has given a return of 142.97% in the last 1 years.

What is the current PB & PE ratio of DICE Therapeutics Inc (DICE)?

Since, TTM earnings of DICE Therapeutics Inc (DICE) is negative, P/E ratio is not available.
The P/B ratio of DICE Therapeutics Inc (DICE) is 5.91 times as on 18-Aug-2023, a 10 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2022	-17.36	-7.56
2021	-19.40	-9.07
2020	--	--
2019	--	--
2022	-17.36	-7.56

What is the 52 Week High and Low of DICE Therapeutics Inc (DICE)?

The 52-week high and low of DICE Therapeutics Inc (DICE) are Rs -- and Rs -- as of 28-Aug-2026.

What is the market cap of DICE Therapeutics Inc (DICE)?

DICE Therapeutics Inc (DICE) has a market capitalisation of $ 2,271 Mln as on 18-Aug-2023. As per SEBI classification, it is a Small Cap company.

Should I invest in DICE Therapeutics Inc (DICE)?

Before investing in DICE Therapeutics Inc (DICE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.